PATENT CLAIM ANALYSIS

Application Number: 15940063
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "460000"]

Abstract:
The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.

Claim (Index 62):
The pharmaceutical formulation of  claim 61 , wherein each modified-release particle contains:\n about 12% by weight antimethanogenic statin; about 61% by weight microcrystalline cellulose; about 6% by weight copovidone; about 2% by weight silicon dioxide; about 1% by weight magnesium stearate; about 5% by weight crospovidone; and about 15% by weight of the first or the second enteric polymer; and about 7 mg of the antimethogenic statin.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 90.0
- Lexical Diversity: 1.26829
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14826115', '10967167', '15043223', '15810891', '14211197']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7560131609116061
- 35 USC 102 Novelty (BERT): 0.6002191882423834
- Combined Prediction Score: 0.7404337636446838
- Mean Citation Score: 268.555658
- Max Citation Score: 516.33484
- Similarity Product: 477.2205096558046

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test